National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 35941-35942 [2020-12679]
Download as PDF
<![CDATA[
35941
Federal Register / Vol. 85, No. 114 / Friday, June 12, 2020 / Notices
Comments on this ICR must be
received no later than July 13, 2020.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under Review—Open for
Public Comments’’ or by using the
search function.
FOR FURTHER INFORMATION CONTACT: To
request a copy of the clearance requests
submitted to OMB for review, email Lisa
Wright-Solomon, the HRSA Information
Collection Clearance Officer at
paperwork@hrsa.gov or call (301) 443–
1984.
SUPPLEMENTARY INFORMATION: When
submitting comments or requesting
information, please include the ICR title
for reference.
Information Collection Request Title:
Evaluation of the Maternal and Child
Health Bureau’s Autism CARES Act
Initiative, OMB No. 0915–0335–
Revision.
Abstract: In response to the growing
need for research and resources devoted
to autism spectrum disorder and other
developmental disabilities, the U.S.
Congress passed the Combating Autism
Act of 2006 (Pub. L. 109–416); it was
reauthorized by the Combating Autism
Reauthorization Act of 2011 (Pub. L.
112–32), the Autism Collaboration,
DATES:
Accountability, Research, Education,
and Support (Autism CARES) Act of
2014 (Pub. L. 113–157) and the Autism
CARES Act of 2019 (Pub. L. 116–60).
Through these Autism CARES public
laws, HRSA has been tasked with
increasing awareness of autism
spectrum disorder and developmental
disabilities, reducing barriers to
screening and diagnosis, promoting
evidence-based interventions, and
training healthcare professionals in the
use of valid and reliable diagnostic
tools.
Need and Proposed Use of the
Information: The purpose of this
information collection is to design and
implement an impact evaluation to
assess the effectiveness of HRSA’s
Maternal and Child Health Bureau’s
activities in meeting the goals and
objectives of the Autism CARES Act.
This ICR is a revision to an existing
package; this study is the fourth
evaluation of HRSA’s autism activities
and employs similar data collection
methodologies as the prior studies.
Grantee interviews remain the primary
form of data collection. Minor proposed
revisions to the data collection process
include (1) modifications to the
interview questions based on the
current legislation and HRSA’s Notices
of Funding Opportunity and (2) the
creation of a new Grantee Survey to
collect common data elements across
the three program areas that focus on
training, research, and state systems.
Likely Respondents: Grantees funded
by HRSA’s Autism programs will be the
respondents for this data collection
activity. The grantees are from the
following HRSA programs: Leadership
Education in Neurodevelopmental and
Related Disabilities Training Program;
Developmental Behavioral Pediatrics
Training Program; State Innovation in
Care Integration Program; State
Innovation in Care Coordination
Program; Research Network Program;
Research Program; Interdisciplinary
Technical Assistance Center; and the
State Public Health Autism Center
Resource Center.
Burden Statement: Burden in this
context means the time expended by
persons to generate, maintain, retain,
disclose, or provide the information
requested. This includes the time
needed to review instructions; to
develop, acquire, install, and utilize
technology and systems for the purpose
of collecting, validating, and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information; to search
data sources; to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. The total annual burden
hours estimated for this ICR are
summarized in the table below.
TOTAL ESTIMATED ANNUALIZED BURDEN HOURS
jbell on DSKJLSW7X2PROD with NOTICES
Average
number of
responses per
respondent
Number of
respondents
Grant Program/form name
Average
hours per
response
Total
responses
Total hour
burden
Grantee Survey (Training and Research Grantees) ...........
Grantee Survey (State Systems Grantees) .........................
Training Interview Guide ......................................................
State Systems Interview Guide ...........................................
Research Interview Guide ...................................................
Research Quantitative Data Collection Form ......................
Interdisciplinary Technical Assistance Center Interview
Guide ................................................................................
State Public Health Autism Center Interview Guide ............
80
5
64
5
24
6
3
3
1.5
1.5
1.5
1
240
15
96
7.5
36
6
0.5
........................
1.25
1.25
1
1
120
7.5
120
9.375
36
6
1
1
2
2
2
2
1
1
2
2
Total ..............................................................................
186
........................
404.5
........................
302.9
HRSA specifically requests comments
on (1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions; (2) the accuracy of the
estimated burden; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4) the
use of automated collection techniques
or other forms of information
VerDate Sep<11>2014
17:43 Jun 11, 2020
Jkt 250001
technology to minimize the information
collection burden.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Maria G. Button,
Director, Executive Secretariat.
National Institutes of Health
[FR Doc. 2020–12730 Filed 6–11–20; 8:45 am]
BILLING CODE 4165–15–P
PO 00000
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
Frm 00046
Fmt 4703
Sfmt 4703
E:\FR\FM\12JNN1.SGM
12JNN1
35942
Federal Register / Vol. 85, No. 114 / Friday, June 12, 2020 / Notices
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The cooperative agreement
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the cooperative agreement applications,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Implementation Cooperative Agreement (U01
Clinical Trial Required).
Date: June 30, 2020.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5600 Fishers Lane, Room 3F21B,
Rockville, MD 20892 (Telephone Conference
Call).
Contact Person: Maryam Feili-Hariri,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F21B,
Bethesda, MD 20892–9834, (240) 669–5026,
haririmf@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: June 8, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–12679 Filed 6–11–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
jbell on DSKJLSW7X2PROD with NOTICES
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
VerDate Sep<11>2014
17:43 Jun 11, 2020
Jkt 250001
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; CEIRR Influenza Data
Processing and Communication Center (N01).
Date: July 9, 2020.
Time: 10:00 a.m. to 1:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room #3E72A,
Rockville, MD 20892 (Telephone Conference
Call).
Contact Person: Frank S. De Silva, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room #3E72A, Rockville, MD
20892–9823, (240) 669–5023, fdesilva@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: June 8, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–12678 Filed 6–11–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Chronic Disease
Disparities competing supplements.
Date: July 20, 2020.
PO 00000
Frm 00047
Fmt 4703
Sfmt 9990
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Michele L. Barnard, Ph.D.,
Scientific Review Officer, Review Branch,
Division of Extramural Activities, NIDDK,
National Institutes of Health, Room 7353,
6707 Democracy Boulevard, Bethesda, MD
20892–2542, (301) 594–8898, barnardm@
extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Chronic Disease
Disparities RFA Kidney and Urology.
Date: July 21, 2020.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Michele L. Barnard, Ph.D.,
Scientific Review Officer, Review Branch,
Division of Extramural Activities, NIDDK,
National Institutes of Health, Room 7353,
6707 Democracy Boulevard, Bethesda, MD
20892–2542, (301) 594–8898, barnardm@
extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Chronic Disease
Disparities RFA Endocrine and GI.
Date: July 28, 2020.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Michele L. Barnard, Ph.D.,
Scientific Review Officer, Review Branch,
Division of Extramural Activities, NIDDK,
National Institutes of Health, Room 7353,
6707 Democracy Boulevard, Bethesda, MD
20892–2542, (301) 594–8898, barnardm@
extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: June 8, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–12682 Filed 6–11–20; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\12JNN1.SGM
12JNN1
]]>Agencies
[Federal Register Volume 85, Number 114 (Friday, June 12, 2020)]
[Notices]
[Pages 35941-35942]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-12679]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
[[Page 35942]]
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The cooperative agreement applications and the
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the cooperative agreement
applications, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; NIAID Clinical Trial Implementation
Cooperative Agreement (U01 Clinical Trial Required).
Date: June 30, 2020.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate cooperative agreement
applications.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5600 Fishers Lane, Room 3F21B,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Maryam Feili-Hariri, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3F21B,
Bethesda, MD 20892-9834, (240) 669-5026, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: June 8, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-12679 Filed 6-11-20; 8:45 am]
BILLING CODE 4140-01-P
